Related Experiment Videos
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer
1Division of Oncology, University of Washington, Seattle 98195, USA.
Abstract:
The HER-2/neu oncogenic protein is a tumor antigen. Some patients with cancer have a preexistent immune response directed against the HER-2/neu protein. Effective cancer vaccines targeting HER-2/neu will be able to boost this immunity to potentially therapeutic levels. In addition, HER-2/neu-directed monoclonal antibody therapy has been effective in eradicating malignancy in animal models and has shown benefit in the treatment of human HER-2/neu-overexpressing cancers. This review outlines studies that define HER-2/neu-specific immunity in patients with cancer and overviews the current vaccine strategies for generating or augmenting neu-specific immunity. The potential problems associated with eliciting HER-2/neu-specific immunity are addressed, including the question of precipitating autoimmune toxicity against this "self" -protein and the mechanisms of immunological escape that may play a role in preventing effective function of the HER-2/neu-specific immune response. Finally, antibody-based HER-2/neu-directed therapies are overviewed. HER-2/neu is a prototype antigen for groups investigating innovative modifications of monoclonal antibody technology, and cutting edge therapies targeting this antigen are being contemplated for clinical use in the treatment of human malignancy. Immune-based treatments designed to target the HER-2/neu oncogenic protein will soon give the clinical oncologist new therapeutic weapons, directed against a biologically relevant tumor-related protein, with which to fight cancer.
Insights
Cancer vaccines and monoclonal antibodies targeting the HER-2/neu protein can enhance anti-tumor immunity. This review explores HER-2/neu immunity, vaccine strategies, and antibody therapies for cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- The HER-2/neu protein is a tumor antigen found in some cancers.
- Pre-existing immune responses against HER-2/neu exist in some cancer patients.
- HER-2/neu overexpression is linked to malignancy and is a target for therapeutic intervention.
Purpose of the Study:
- To review HER-2/neu-specific immunity in cancer patients.
- To overview current vaccine strategies for augmenting HER-2/neu immunity.
- To discuss antibody-based therapies targeting HER-2/neu.
Main Methods:
- Literature review of studies on HER-2/neu immunity and therapies.
- Analysis of vaccine strategies for generating or boosting HER-2/neu-specific immune responses.
- Overview of monoclonal antibody therapy applications in HER-2/neu-overexpressing cancers.
Main Results:
- HER-2/neu-directed vaccines show potential to boost anti-tumor immunity.
- Monoclonal antibody therapy has demonstrated efficacy in preclinical models and human cancers.
- Challenges include potential autoimmune toxicity and immunological escape mechanisms.
Conclusions:
- Immune-based treatments targeting HER-2/neu are emerging as significant therapeutic options.
- HER-2/neu serves as a prototype for developing novel antibody technologies.
- Targeting HER-2/neu offers new weapons for oncologists against human malignancy.